New innovations targeting dry eye disease (DED) are in the pipeline to enable us to tailor our treatments to the specific underlying causes of DED. Here, we discuss a handful of the new treatment options in development.

• Reproxalap (Aldeyra Therapeutics). This is a reactive aldehyde species modulator that may be effective in decreasing inflammation in both DED and allergy patients. It is currently undergoing phase 3 clinical trials.
• AZR-MD-001 (Azura Ophthalmics). This is an ophthalmic ointment currently in phase 3 trials. It may improve the quality of meibum in patients who have meibomian gland dysfunction.

• OCS-02 (licaminlimab; Oculis). This is currently in phase 2 trials. It is an anti-TNFa drop specifically developed to treat ocular inflammation and apoptosis associated with DED.

• Softacort (hydrocortisone sodium; Laboratorios Thea). This is currently in phase 4 trials. As an anti-inflammatory, when supplemented with consistent warm compress and lid hygiene habits, it may provide relief for patients who have meibomian gland dysfunction. OM